Feasibility and patient acceptability of a commercially available wearable and a smart phone application in identification of motor states in parkinson’s disease

In the quantification of symptoms of Parkinson’s disease (PD), healthcare professional assessments, patient reported outcomes (PRO), and medical device grade wearables are currently used. Recently, also commercially available smartphones and wearable devices have been actively researched in the dete...

Full description

Saved in:
Bibliographic Details
Published inPLOS digital health Vol. 2; no. 4; p. e0000225
Main Authors Liikkanen, Sammeli, Sinkkonen, Janne, Suorsa, Joni, Kaasinen, Valtteri, Pekkonen, Eero, Kärppä, Mikko, Scheperjans, Filip, Huttunen, Teppo, Sarapohja, Toni, Pesonen, Ullamari, Kuoppamäki, Mikko, Keränen, Tapani
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 01.04.2023
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:In the quantification of symptoms of Parkinson’s disease (PD), healthcare professional assessments, patient reported outcomes (PRO), and medical device grade wearables are currently used. Recently, also commercially available smartphones and wearable devices have been actively researched in the detection of PD symptoms. The continuous, longitudinal, and automated detection of motor and especially non-motor symptoms with these devices is still a challenge that requires more research. The data collected from everyday life can be noisy and frequently contains artefacts, and novel detection methods and algorithms are therefore needed. 42 PD patients and 23 control subjects were monitored with Garmin Vivosmart 4 wearable device and asked to fill a symptom and medication diary with a mobile application, at home, for about four weeks. Subsequent analyses are based on continuous accelerometer data from the device. Accelerometer data from the Levodopa Response Study (MJFFd) were reanalyzed, with symptoms quantified with linear spectral models trained on expert evaluations present in the data. Variational autoencoders (VAE) were trained on both our study accelerometer data and on MJFFd to detect movement states (e.g., walking, standing). A total of 7590 self-reported symptoms were recorded during the study. 88.9% (32/36) of PD patients, 80.0% (4/5) of DBS PD patients and 95.5% (21/22) of control subjects reported that using the wearable device was very easy or easy. Recording a symptom at the time of the event was assessed as very easy or easy by 70.1% (29/41) of subjects with PD. Aggregated spectrograms of the collected accelerometer data show relative attenuation of low (<5Hz) frequencies in patients. Similar spectral patterns also separate symptom periods from immediately adjacent non-symptomatic periods. Discriminative power of linear models to separate symptoms from adjacent periods is weak, but aggregates show partial separability of patients vs. controls. The analysis reveals differential symptom detectability across movement tasks, motivating the third part of the study. VAEs trained on either dataset produced embedding from which movement states in MJFFd could be predicted. A VAE model was able to detect the movement states. Thus, a pre-detection of these states with a VAE from accelerometer data with good S/N ratio, and subsequent quantification of PD symptoms is a feasible strategy. The usability of the data collection method is important to enable the collection of self-reported symptom data by PD patients. Finally, the usability of the data collection method is important to enable the collection of self-reported symptom data by PD patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
The Authors have read the journal’s policy and the authors of this manuscript have the following competing interests: Sammeli Liikkanen, Toni Sarapohja and Mikko Kuoppamäki are employees of Orion Corporation Orion Pharma, Finland. Janne Sinkkonen, Joni Suorsa and Teppo Huttunen were paid consultants of Orion Corporation Orion Pharma, Finland. Valtteri Kaasinen has received honoraria for lecturing from Nordic Infucare and Abbvie; is a member of advisory board of Abbvie, Nordic Infucare; has received consulting fees from Orion Pharma, Adamant Health, Abbvie and Nordic Infucare; and has participated in clinical trials of Orion Pharma. Eero Pekkonen is a member of the MDS Non-Motor Parkinson’s Disease Study Group, has been a PI in Finland in International ADROIT study (Abbott DBS Registry of Outcomes for Indications over Time), is a consulting neurologist for Patient Insurance Centre of Finland, is a member of advisory board for Abbvie, Nordic Infucare, has received consulting fees from Boston Scientific, Nordic Infucare AB and Abbvie, and has received lecture fees from Abbvie, Nordic InfuCare. Filip Scheperjans is founder and CEO of NeuroInnovation Oy and NeuroBiome Ltd., is a member of the scientific advisory board and has received consulting fees and stock options from Axial Biotherapeutics; has received grants from The Academy of Finland, The Hospital District of Helsinki and Uusimaa, OLVI-Foundation, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, The Wilhelm and Else Stockmann Foundation, The Emil Aaltonen Foundation, The Yrjö Jahnsson Foundation, Renishaw, and honoraria from AbbVie, Orion, GE Healthcare, Merck, Teva, Bristol Myers Squibb, Sanofi, and Biogen. Ullamari Pesonen is doing collaboration projects with Orion Pharma. Tapani Keränen has received compensation from Orion Pharma for the work related to this study.
ISSN:2767-3170
2767-3170
DOI:10.1371/journal.pdig.0000225